Immunitybio Inc (IBRX) support and resistance · rev $113.3M
Immunitybio Inc (IBRX) is a biotechnology company listed on US.
This page maps Immunitybio Inc (IBRX) support and resistance from cached range and valuation — not a live tape and not a trade alert.
Latest reported IBRX revenue for 2025-12-31 was $113.3M. Net income was -$351.4M. Revenue was up 668.3% from 2024-12-31 to 2025-12-31. IBRX currently screens at market cap $7.88B.
IBRX currently screens at market cap $7.88B. Round numbers near that cap and multiple often act as psychological resistance; prior-period revenue is the fundamental floor traders argue about.
A new IBRX 8-K or 10-Q can move the levels that matter more than a drawing on a chart.
Not investment advice. Use the IBRX quote page for the session range and the stock page for the full model.
Not investment advice.